6ddv: Difference between revisions
No edit summary |
No edit summary |
||
| Line 3: | Line 3: | ||
<StructureSection load='6ddv' size='340' side='right' caption='[[6ddv]], [[Resolution|resolution]] 2.05Å' scene=''> | <StructureSection load='6ddv' size='340' side='right' caption='[[6ddv]], [[Resolution|resolution]] 2.05Å' scene=''> | ||
== Structural highlights == | == Structural highlights == | ||
<table><tr><td colspan='2'>[[6ddv]] is a 3 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6DDV OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6DDV FirstGlance]. <br> | <table><tr><td colspan='2'>[[6ddv]] is a 3 chain structure with sequence from [http://en.wikipedia.org/wiki/Human Human] and [http://en.wikipedia.org/wiki/Lk3_transgenic_mice Lk3 transgenic mice]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6DDV OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6DDV FirstGlance]. <br> | ||
</td></tr><tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6ddv FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6ddv OCA], [http://pdbe.org/6ddv PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=6ddv RCSB], [http://www.ebi.ac.uk/pdbsum/6ddv PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=6ddv ProSAT]</span></td></tr> | </td></tr><tr id='gene'><td class="sblockLbl"><b>[[Gene|Gene:]]</b></td><td class="sblockDat">MICA ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN])</td></tr> | ||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6ddv FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6ddv OCA], [http://pdbe.org/6ddv PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=6ddv RCSB], [http://www.ebi.ac.uk/pdbsum/6ddv PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=6ddv ProSAT]</span></td></tr> | |||
</table> | </table> | ||
<div style="background-color:#fffaf0;"> | <div style="background-color:#fffaf0;"> | ||
| Line 19: | Line 20: | ||
__TOC__ | __TOC__ | ||
</StructureSection> | </StructureSection> | ||
[[Category: Human]] | |||
[[Category: Lk3 transgenic mice]] | |||
[[Category: Matsumoto, M L]] | [[Category: Matsumoto, M L]] | ||
[[Category: Fab fragment-antigen complex]] | [[Category: Fab fragment-antigen complex]] | ||
[[Category: Immune system]] | [[Category: Immune system]] | ||
[[Category: Immunoglobulin domain]] | [[Category: Immunoglobulin domain]] | ||
Revision as of 10:02, 5 December 2018
Crystal Structure Analysis of the Epitope of an Anti-MICA AntibodyCrystal Structure Analysis of the Epitope of an Anti-MICA Antibody
Structural highlights
Publication Abstract from PubMedAs an immune evasion strategy, MICA and MICB, the major histocompatibility complex class I homologs, are proteolytically cleaved from the surface of cancer cells leading to impairment of CD8 + T cell- and natural killer cell-mediated immune responses. Antibodies that inhibit MICA/B shedding from tumors have therapeutic potential, but the optimal epitopes are unknown. Therefore, we developed a high-resolution, high-throughput glycosylation-engineered epitope mapping (GEM) method, which utilizes site-specific insertion of N-linked glycans onto the antigen surface to mask local regions. We apply GEM to the discovery of epitopes important for shedding inhibition of MICA/B and validate the epitopes at the residue level by alanine scanning and X-ray crystallography (Protein Data Bank accession numbers 6DDM (1D5 Fab-MICA*008), 6DDR (13A9 Fab-MICA*008), 6DDV (6E1 Fab-MICA*008). Furthermore, we show that potent inhibition of MICA shedding can be achieved by antibodies that bind GEM epitopes adjacent to previously reported cleavage sites, and that these anti-MICA/B antibodies can prevent tumor growth in vivo. High-resolution glycosylation site-engineering method identifies MICA epitope critical for shedding inhibition activity of anti-MICA antibodies.,Lombana TN, Matsumoto ML, Bevers Iii J, Berkley AM, Toy E, Cook R, Gan Y, Du C, Liu P, Schnier P, Sandoval W, Ye Z, Schartner JM, Kim J, Spiess C MAbs. 2018 Oct 11. doi: 10.1080/19420862.2018.1532767. PMID:30307368[1] From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine. References
|
| ||||||||||||||||